Literature DB >> 27604228

Acute Myeloid Leukemia: How Do We Measure Success?

Joshua P Sasine1, Gary J Schiller2.   

Abstract

The development and approval of novel, effective therapies for acute myeloid leukemia (AML) has lagged behind other malignancies. Judging success of therapy with meaningful endpoints is critical to development of new treatments. Overall survival (OS) has typically been the parameter necessary for regulatory approval of experimental therapy in AML. Herein, we discuss different strategies to define outcomes for patients with AML and their relative challenges.

Entities:  

Keywords:  Acute myeloid leukemia; Event-free survival; Overall survival; Therapy

Mesh：

Substances：

Year:  2016        PMID： 27604228     DOI： 10.1007/s11899-016-0346-x

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  70 in total

1.  Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.

Authors:  A Venditti; F Buccisano; G Del Poeta; L Maurillo; A Tamburini; C Cox; A Battaglia; G Catalano; B Del Moro; L Cudillo; M Postorino; M Masi; S Amadori
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

3.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

4.  Chemosensitizing AML cells by targeting bone marrow endothelial cells.

Authors:  Raphael C Bosse; Briana Wasserstrom; Amy Meacham; Elizabeth Wise; Leylah Drusbosky; Glenn A Walter; David J Chaplin; Dietmar W Siemann; Daniel L Purich; Christopher R Cogle
Journal:  Exp Hematol       Date:  2016-02-16       Impact factor: 3.084

5.  Functional Niche Competition Between Normal Hematopoietic Stem and Progenitor Cells and Myeloid Leukemia Cells.

Authors:  Chen Glait-Santar; Ronan Desmond; Xingmin Feng; Taha Bat; Jichun Chen; Elisabeth Heuston; Benjamin Mizukawa; James C Mulloy; David M Bodine; Andre Larochelle; Cynthia E Dunbar
Journal:  Stem Cells       Date:  2015-10-05       Impact factor: 6.277

6.  Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.

Authors:  Wolfgang Kern; Daniela Voskova; Claudia Schoch; Wolfgang Hiddemann; Susanne Schnittger; Torsten Haferlach
Journal:  Blood       Date:  2004-07-29       Impact factor: 22.113

7.  Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse.

Authors:  Jason E Farrar; Heather L Schuback; Rhonda E Ries; Daniel Wai; Oliver A Hampton; Lisa R Trevino; Todd A Alonzo; Jaime M Guidry Auvil; Tanja M Davidsen; Patee Gesuwan; Leandro Hermida; Donna M Muzny; Ninad Dewal; Navin Rustagi; Lora R Lewis; Alan S Gamis; David A Wheeler; Malcolm A Smith; Daniela S Gerhard; Soheil Meshinchi
Journal:  Cancer Res       Date:  2016-03-03       Impact factor: 12.701

8.  The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo.

Authors:  E Todisco; F Ciceri; E Oldani; C Boschini; C Micò; M T Vanlint; I Donnini; F Patriarca; P E Alessandrino; F Bonifazi; W Arcese; W Barberi; P Marenco; E Terruzzi; S Cortelazzo; S Santarone; A Proia; P Corradini; E Tagliaferri; S Falcioni; G Irrera; L Dallanegra; L Castagna; A Santoro; A Camboni; N Sacchi; A Bosi; A Bacigalupo; A Rambaldi
Journal:  Leukemia       Date:  2013-07-09       Impact factor: 11.528

9.  Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.

Authors:  Y Zhou; M Othus; D Araki; B L Wood; J P Radich; A B Halpern; M Mielcarek; E H Estey; F R Appelbaum; R B Walter
Journal:  Leukemia       Date:  2016-02-29       Impact factor: 11.528

10.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962
View more
  6 in total

Review 1.  The biomarkers of leukemia stem cells in acute myeloid leukemia.

Authors:  Yahui Ding; Huier Gao; Quan Zhang
Journal:  Stem Cell Investig       Date:  2017-03-02

2.  Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche.

Authors:  Allison L Boyd; Jennifer C Reid; Kyle R Salci; Lili Aslostovar; Yannick D Benoit; Zoya Shapovalova; Mio Nakanishi; Deanna P Porras; Mohammed Almakadi; Clinton J V Campbell; Michael F Jackson; Catherine A Ross; Ronan Foley; Brian Leber; David S Allan; Mitchell Sabloff; Anargyros Xenocostas; Tony J Collins; Mickie Bhatia
Journal:  Nat Cell Biol       Date:  2017-10-16       Impact factor: 28.824

Review 3.  Diagnostic and Prognostic Utility of Fluorescence In situ Hybridization (FISH) Analysis in Acute Myeloid Leukemia.

Authors:  Patrick R Gonzales; Fady M Mikhail
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

4.  Extracellular vesicles impose quiescence on residual hematopoietic stem cells in the leukemic niche.

Authors:  Sherif Abdelhamed; John T Butler; Ben Doron; Amber Halse; Eneida Nemecek; Phillip A Wilmarth; Daniel L Marks; Bill H Chang; Terzah Horton; Peter Kurre
Journal:  EMBO Rep       Date:  2019-06-17       Impact factor: 8.807

5.  Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021.

Authors:  Tariq I Mughal; Bethan Psaila; Daniel J DeAngelo; Giuseppe Saglio; Richard A Van Etten; Jerald P Radich
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

6.  DesA Prognostic Risk Model of LncRNAs in Patients With Acute Myeloid Leukaemia Based on TCGA Data.

Authors:  Weidong Ding; Yun Ling; Yuan Shi; Zhuojun Zheng
Journal:  Front Bioeng Biotechnol       Date:  2022-02-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.